{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:17:29Z","timestamp":1792081049342,"version":"4.4.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014098","name":"Ren\u00e9 Vogels Stichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RE 4782\/1-2"],"award-info":[{"award-number":["RE 4782\/1-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.urolonc.2024.01.027","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T09:17:13Z","timestamp":1710235033000},"page":"177.e5-177.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1161-4196","authenticated-orcid":false,"given":"Moritz J.","family":"Reike","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep J.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek A.","family":"Bismar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Boorjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Y.","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Dall'Era","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hristros Z.","family":"Kaimakliotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost L.","family":"Boormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewan A.","family":"Gibb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2024.01.027_bib0001","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.01.027_bib0002","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"issue":"2 Pt 1","key":"10.1016\/j.urolonc.2024.01.027_bib0003","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/01.ju.0000090967.08622.33","article-title":"Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis","volume":"171","author":"Winquist","year":"2004","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.urolonc.2024.01.027_bib0004","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.urolonc.2024.01.027_bib0005","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","year":"2005","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.01.027_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100416","article-title":"Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer","volume":"7","author":"Beije","year":"2022","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.urolonc.2024.01.027_bib0007","doi-asserted-by":"crossref","first-page":"565","DOI":"10.4111\/icu.20200132","article-title":"Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer","volume":"61","author":"McFerrin","year":"2020","journal-title":"Investig Clin Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.01.027_bib0008","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2019.04.036","article-title":"Molecular subtyping of clinically localized urothelial carcinoma reveals lower rates of pathological upstaging at radical cystectomy among luminal tumors","volume":"76","author":"Lotan","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.01.027_bib0009","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.urolonc.2024.01.027_bib0010","doi-asserted-by":"crossref","first-page":"540-56 e25","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.urolonc.2024.01.027_bib0011","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.01.027_bib0012","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2021.10.035","article-title":"Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes","volume":"81","author":"Sj\u00f6dahl","year":"2022","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.01.027_bib0013","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/JU.0000000000002261","article-title":"Patients with muscle-invasive bladder cancer with nonluminal subtype derive greatest benefit from platinum based neoadjuvant chemotherapy","volume":"207","author":"Lotan","year":"2021","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.01.027_bib0014","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"issue":"16","key":"10.1016\/j.urolonc.2024.01.027_bib0015","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1158\/1078-0432.CCR-18-1106","article-title":"Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer","volume":"25","author":"Seiler","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2024.01.027_bib0016","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.eururo.2021.12.032","article-title":"Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes","volume":"81","author":"De Jong","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.01.027_bib0017","doi-asserted-by":"crossref","unstructured":"De Jong JJ, Gibb EA. Re: Gottfrid Sj\u00f6dahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316\u20137.: Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature? Eur Urol. 2021;81(4):e90\u2013e1.","DOI":"10.1016\/j.eururo.2021.12.033"},{"issue":"7","key":"10.1016\/j.urolonc.2024.01.027_bib0018","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.3390\/cancers14071692","article-title":"Molecular subtypes as a basis for stratified use of neoadjuvant chemotherapy for muscle-invasive bladder cancer-a narrative review","volume":"14","author":"Sjodahl","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.urolonc.2024.01.027_bib0019","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.euo.2019.06.002","article-title":"Can biomarkers guide the use of neoadjuvant chemotherapy in T2 bladder cancer?","volume":"2","author":"Grossman","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.01.027_bib0020","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ygeno.2012.08.003","article-title":"A single-sample microarray normalization method to facilitate personalized-medicine workflows","volume":"100","author":"Piccolo","year":"2012","journal-title":"Genomics"},{"issue":"1","key":"10.1016\/j.urolonc.2024.01.027_bib0021","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4886","article-title":"Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification","volume":"242","author":"Sjodahl","year":"2017","journal-title":"J Pathol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.01.027_bib0022","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"issue":"12","key":"10.1016\/j.urolonc.2024.01.027_bib0023","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sjodahl","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.urolonc.2024.01.027_bib0024","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eururo.2020.02.028","article-title":"Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.01.027_bib0025","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13073-019-0669-z","article-title":"Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis","volume":"11","author":"de Jong","year":"2019","journal-title":"Genome Med"},{"key":"10.1016\/j.urolonc.2024.01.027_bib0026","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"issue":"30","key":"10.1016\/j.urolonc.2024.01.027_bib0027","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1002\/sim.7084","article-title":"Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis","volume":"35","author":"Austin","year":"2016","journal-title":"Stat Med"},{"issue":"5","key":"10.1016\/j.urolonc.2024.01.027_bib0028","first-page":"360","article-title":"Understanding interobserver agreement: the kappa statistic","volume":"37","author":"Viera","year":"2005","journal-title":"Fam Med"},{"issue":"1","key":"10.1016\/j.urolonc.2024.01.027_bib0029","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1038\/s41467-020-18640-0","article-title":"Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis","volume":"11","author":"Taber","year":"2020","journal-title":"Nat Commun"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924000437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924000437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T22:26:06Z","timestamp":1713997566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924000437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1078143924000437"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.01.027","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}